and you, our afternoon, joining everyone, and good for call. thanks Thank Mark,
times, and the As said well-being daily remained suffering is world mission, disrupt their has are many radically wide before, mental and millions our other our improve steadfast that disorders who team of I've variety which severely CNS in the around individuals of from anxiety, to health depression of a lives. core
a over focused solidified cornerstone lives anxiety for on safety individuals And by SAD. of social or mission who There's often in are currently indeed the potential the as need an we've recently that of in SAD new that medicines. affected approved we've disorder improving major the announced, side XX abuse million faster-acting concerns treatment growing the for with a active effects and and option associated are or America without
for diverse addressing focused remain We communities in across globe. range significant need of on the range of and health demographics - across health individuals a mental a unmet broad this
depression in for other treatments to our alignment multiple paradigm with shift to committed We're differentiated the and innovation disorders. treatment anxiety, of mission CNS multiple
leadership Phase and announced treatment a our from changed get the are we top on in biggest company's line brought let's since new to with conference optimism positive the and PALISADE-X trial for news in disorder, X position So a a long to thrilled has It's compelling in our study of lot's since right history. call, our Monday. a been be that social last Phase anxiety X were results time
are millions what's and affected the mechanism of SAD more with individuals millions fasedienol in action to highlight U.S. Phase possible for results X with its These the of who proposed transform for living worldwide. potential innovative
clinically and fasedienol meaningful reduce In distressed helps the rapid the a anxiety has PALISADE-X administration or inhaler the rapidly that SUDS potential reduction demonstrated subjective a how rescue to asthma. during person indicating single on-demand units a score used symptoms of with score, of in anxiety-provoking similar study, situation perhaps to SUDS, fasedienol a an
safety was public placebo-controlled and this to or four placebo, recap, throughout where at patient a intervals challenge second a SUDS one To to multicenter, clinic challenge randomized after U.S. apart, nasal X. subjects challenge, spray, a captured week and after were were visit, public improvement the were of a speaking follow-up Phase trial challenge physician administration a screening X out speaking a double-blind, assessment by visit. baseline were second visits captured randomized, scores of consisting then placebo of patients that spaced fasedienol completed minute visit each either public a a at speaking setting speaking was
order randomization second anxiety levels high of progress had baseline of In to first speaking X, public or speaking public visit the the challenge, the exhibit to challenge. challenge subjects the during
SAD and on were study score above receiving active the Scale, confirmed primary of as currently disorders Liebowitz Anxiety not medications. the to or XX the referred Social is CNS without other commonly psychiatric which with a in patients LSAS, Patients
from in were fasedienol independent and the to who had trial In on conduct total, to top we patients an of after pause. the date trial, The XX randomized in XXX allow analysis receive enrollment completed pause XX for XXX line placebo. subjects up to and of reflects the the on the PALISADE-X were the total biostatisticians results interim randomized enrollment
impending interim the business results PALISADE-X the for continuation would pending and FDA implications regarding of two of logistical regulatory PALISADE-X. a of continuing by assessment studies conducted SAD be resuming or primary the in as the safety the well the for to further treatment the the of public PALISADE end top with pause assessment challenges of the studies not results as statistical the open-label study, indicated companies, results extend as Although X futile, the discussions SAD line PALISADE-X, Phase peer we challenge of LSAS important elected acceptability speaking time, comprehensive our point of our reasons, of with analysis then independent associated efficacy of expense, and our assessment
randomize about than XXX the study, XXXX studies subjects from reliability rather the LSAS FDA point, as a results positive additional SAD positive continuing for the by validity and chose as not strategic end we PALISADE with discussions their point speaking completed measured our early conducted a study with of efficacy total did the the Following XXX close of primary subjects planned. originally XX two reasons, PALISADE-X the public subjects of for as and end of an each by resume to our open and challenge SUDS companies, results efficacy in which meet primary peer the label
to subjects was compromised visit through simply in The to error analysis. treat result and PALISADE-X primary was during patients because a baseline mean altered the similar PALISADE-X at challenge fasedienol study did XXX. who X The was two way. of treatment score PALISADE-X end originally three that planned visit not SUDS interim process, important plan was an type speaking not point require for in originally followed of correction note to XXX a planned. It stopped as the the any with blind this compared in a altered the of very placebo. and public statistical never to and analysis the population instead It's early as intention not was It was was receive difference
captured SUDS a compared on change demonstrated greater of in single a highly statistically a provocative with reduction points a in believe they're challenge for XX.X these dose a the of a in speaking points score groups reduction exploratory mean patients to considering results of difference We fasedienol responder supported and based of with least-squares p-value to rates be end of Fasedienol-treated between a clinically and secondary X.XXX. is significant, X.X high significant especially public points. by X
as those as to as of three point, responders fasedienol-treated Responders a compared or clinician-assessed or very less anxious XX.X% with a measured as after placebo, those identified of CGI-I. treated had end patients with Impressions X.XXX. demonstrated the study proportion Fasedienol who as Global of statistically versus less scale XX.X% were the significant by rated secondary much the visit p-value CGI-I. responders of rated difference Clinical were anxious The a with in much Improvement placebo
in visit recognized that the able study of with Very with X, to less their an as improvement the PALISADE-X very challenges. end had on have X.XXX. two after with XX.X% scale excited identified Plus, much Patient's responders to PGI-I. on patient's those Global speaking treated that fasedienol about public were exploratory physicians because compared self-rated as impressive responders rated a anxious XX.X% anxious as of the scale these only less of The even improvement placebo also themselves fasedienol on p-value an patients fasedienol-treated between clearly demonstrate week or point. who those results were or Impression ability Change patients full recognize to of much
placebo double that their for ability could clearly you the responder and to to and illustrates our over Phase as their as they their highly events more anxiety potential study - patients of in rate of placebo-controlled is open less the use open crossover of This the think speech X PALISADE engage situations, than us in LSAS label to when time, relevant and provoking clinically from patients to study. especially fear with saw about and fasedienol improvement rate avoidance continued deliver reduced we data label our appreciate
visit by XX patients the other almost was three by exploratory points the improved double of rate end placebo addition, XX.X% placebo. to than at point, - more XX on more of In fasedienol other with or dropping points or patients important fasedienol percentage XX.X% compared SUDS of the who
adverse likely to PALISADE all our fasedienol anxiety-provoking XXX PALISADE-X an there over A in in a prior ability clinically were event of X.X%. rate that XX-point makes similar open improving well included engage large fasedienol adverse studies that that with drop occurring standpoint, no was in the doses relevant including at no XX,XXX very serious and study or event. study, above date, events, administered in of label severe treatment-emergent and a to is completed patient's a From and difference of was to subjects tolerated fasedienol safety
end result the compare point in let's efficacy in point PALISADE-X. the PALISADE-X now to primary So primary end
variability it's positive many to unexpected placebo such potential - mental negative have and and have be that particularly the used and studies of subject effects design, given and As we in the of scales that high subject both uncommon similar as for in saw in the not studies health to true in studies scales studies PALISADE-X. know, separate you of
likely PALISADE-X. effect outcome you public task a an and during was mental even numerous PALISADE-X of of compared key consistently in This public difference crisis health across pandemic, speaking the placebo higher sites unprecedented The becomes challenge in add PALISADE-X much the a administering to complex epidemic. more when health
PALISADE-X in in a the end mean fasedienol the point primary, placebo p-value points. and results three effect the SUDS studies to was for true across X.XXX. visit the XX.X change least-squares and of two drug generally This a points The secondary from points of was in end both primary for with The visit of was similar. exploratory end XX.X
that systemic the these wave was PALISADE-X believe and very variability height very of fielded large A We introduced second XXXX the firmly these the of to pandemic by of two in pandemic. studies. through the unexpected different portion results between the contributed
pandemic. the and was execution were likely in majority were the and overall the While in the of different like anxiety of XXXX mindset, and dynamic oversight. study during terms impacted fielded This acute randomized has pandemic disproportionately Subjects of general the XXXX the and protocol vast patient mask as of unrest, restrictions, PALISADE-X given wearing in PALISADE-X level acute subsided. - given study phase likely the of uncertainty phase
lapses in high by changes patients travel, two to COVID-XX clinical and and the visit attributed employee delayed like. visits placebo between and unpredictable PALISADE-X to caused site site in and high closures and turnover, also postponing may as CRO logistical in absenteeism, issues monitoring rate visit time have such three 'XX due raters, The intermittent
the of apparent too, went much in PALISADE-X became a dynamics majority impact pandemic studies. we phase may it and subsided completed as these was patients acute on And had staggered with is customary XXXX, study. retraining early As of also the have that, of as as that before initiated through sites renewed monitoring larger replicate the start
given by study, strong as point label results the driven Phase aforementioned the This studies multiple of seen the potential peers X highly outlier, PALISADE-X positive variability pandemic. meaningful exploratory we and after efficacy of multiple the results our studies recent an the on in view future end been from Phase the studies, trial. PALISADE-X reasons, and may failures PALISADE have especially similar the fasedienol are to subject confident and X is placebo-controlled the in SAD We systemic in open by that now in
meaningful clinically studies FEARLESS potential of the trial PALISADE-X and additional for PALISADE-X, forward a needed move trial, submission, NDA and results statistically plan the Phase X to we're our including confirm a allowing the long With for disease us significant of now with positioned confirm development events to time benefit what fasedienol acute lead acute we've also the of reduction fasedienol use in continued to severity. a not will but only SAD over that believed, to a
Coupled decades primary using efficacy the point. the approach only real-world public initiate PALISADE-X study Preparations speaking with tolerability challenges. to have ago the drugs believe substantially similar and for studies. ideal will as are fasedienol clinic-based now these end trials next demonstrated, profile LSAS the SAD be the underway in design the three of primary already similar for end treatment will for to PALISADE-X be point as future. will the safety the substantially again the we in approved to SAD treatment Protocol to FEARLESS of be with SUDS And we the multi-week registration
As a class, Phase than nasal X our in class across transform treatment fasedienol's pipeline first medicines, in trial. fundamentally new potential, years. stage XX class At numerous stands demonstrated areas. individuals for holds potential of set for more with of spray PALISADE-X the as new pherine living of to the head SAD landscape That X-candidate the the medicine the the therapeutic the
potential collection data confidence pherine our bolster some and pipeline's fasedienol our of of our the growing supporting in promise had advancements other We've programs. gives studies recent us PALISADE-X future clinical in pherine across Positive disorders several evidence, of further overall. untapped
blind, pherine stand-alone trial stage previously itruvone successful investigated was the and brief and adult was look in a on Results Phase for major the rapid-onset single in the and a at the study safety a United development that of MDD. to of take PHXX, conducted spray from Xa successful of multiple Phase build double-blind, a placebo Phase doses candidate itruvone previously in positive studies product randomized, itruvone, Xb disorder, of U.S. and now States placebo-controlled X our or for treatment as double those. referred X healthy in Phase X trial as U.S. of Let's tolerability subjects. Mexico, Phase MDD, controlled, dose depressive in itruvone nasal randomized
There spray events itruvone. with all demonstrated were adverse itruvone studies profile no was well reported adverse discontinuations tolerated and the or that were of favorable due Overall, a serious clinical nasal in events consistent safety to study. prior
without data For radiolabeled of itruvone which also absorption. intranasal Itruvone, its laboratory potential we important rats, preclinical validate in reported further systemic to treat MDD
action limiting circulatory as new proposed peripheral These receptors system of itruvone receptors the potential brain, in nasal not to thereby the minimizing molecules data neurons additionally but nasal cavity exposure. transporter spray to binding to in mechanism the neuronal support systemic of the and of chemosensory
itruvone study development profile. of body favorable MDD case for into preclinical a Phase the safety similar Xb for advancing fasedienol, itruvone's XXXX. data the we was As substantial our further when completed preparations evidence We're with supporting these continuing of in
highly a PHXX excited in We PHXX provides which the optimism spray, Xa recently or pherine Phase hot in positive treatment to nasal indications. very symptoms acute our severe been multiple also which flashes has vasomotor trial nasal reported menopause. spray, women studied of to for due of about exploratory We're moderate new
through the the until hot was the daily each period. end of the improvement compared women, for designed of the In Phase treatment of placebo PHXX of in exploratory the study of week efficacy, double-blind, safety reduction randomized acute end the of treatment first induced treatment, in Xa PHXX was week significant and tolerability of flashes PHXX flashes at placebo-controlled the menopausal explore that to to number a and hot a clinical treatment maintained
placebo mean less the a reported X.X and the in daily group flashes in the subjects treatment, group PHXX hot of of group a in X.X X.X week X.XXX. group and number After the placebo hot number of one to dropped in X.X well. flashes for subjects as of the of p-value of XX subjects of Baseline than XX PHXX
of less number PHXX severity of as the p-value group four the group in reduced disruption X.X to weeks in X.XXX. well placebo sweating as of no a than and and serious flashes after treatment, also PHXX, in comparable significantly during the the treatment hot X.X the for placebo. And to to hot PHXX period our and events event tolerated with flashes PHXX compared related profile and was other between function the the pherines, treatment adverse and placebo. adverse dropped
of subject participation as study All a events. discontinued XX result adverse weeks subjects no and of the completed treatment, four in
the of different indication measure the favorable hot their frequency and be it's flashes have for measures to say symptoms experienced of some how to of more will of in we other these in end this One that additional aspects versus easier in are indications. seen objective running that studies That trials studies. there subjective points those many is particular
of to options. product value deliver expertise partnerships, the amplify successful a and our especially of our and safety activities and our the depth studies development date, We efficacy enhance for we to efficiently both and unlock efforts strategic regional and global development robust Given overall to partnerships portfolio. commercialization pursuing lines global multiple and to key time and entire full commercialization development potential treatment also candidate regional pipeline are and CNS differentiated internal potentially body of our believe accelerate
corporate financials. order as our you We'll We've resources. now burn been to initiatives we've will streamline our to conserve in offer some And cash comments XX-Q shortly. brief implementing reduce in able see our to-be-filed operations our about to rate been
burn We do not anticipate any cash significant near-term increases.
over by an million position, unusually taken gross strengthen of volume balance on the to stock our advantage recently cash expected cash our proceeds. the we've high sheet in in for trading our As position $XX
volume traded of stock $X since results trading - X Monday, of the in days to perspective, into PALISADE-X billion put the put our more trading high has than announcement this trading ago. To this on worth
As Until only May recently, calendar over this is XXXX. with we'd at-the-market years we QX in standard, industry just agreement back two use sparingly back established Jefferies in an of of ago 'XX. very
be do will we forward, and in strengthen strategic well to we options further and remaining wish as our use to should be balance have how sheet ATM our - financing non-dilutive as going Will grants very we other to of continue we this vehicle judicious potential arrangements. continue capacity and plenty so partnering under
mental in in worldwide. health So improve well-being steadfast remain to mission our and closing, we core
the advancing a a move an CNS team, in pipeline drive continue solutions of unmet we markets solid forward for As innovate disorders strong and we unwavering next with plan, corporate needs. our development with care stages large to significant primary better
So on the thank for behalf you difference. team, for of I'd to opportunity a privilege, again the to make Vistagen the like
